Evidence map›Paper›PMID 33274779›Full record

ArticleClinical cardiology2021

Use of risk scores to identify lower and higher risk subsets among COMPASS-eligible patients with chronic coronary syndromes. Insights from the CLARIFY registry.

Arthur Darmon, Gregory Ducrocq, Adam Jasilek, Laurent Feldman, Emmanuel Sorbets, Roberto Ferrari, Ian Ford, Jean-Claude Tardif, Michal Tendera, Kim M Fox and 1 more

Open access · goldAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical cardiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 7 institutions in 5 countries.

Arthur DarmonUniversité de Paris, Assistance Publique-Hôpitaux de Paris, Paris, France.ORCID https://orcid.org/0000-0002-3434-3584
Gregory DucrocqUniversité de Paris, Assistance Publique-Hôpitaux de Paris, Paris, France.ORCID https://orcid.org/0000-0003-4069-1128
Adam JasilekRobertson Centre for Biostatistics, University of Glasgow, Glasgow, UK.
Laurent FeldmanUniversité de Paris, Assistance Publique-Hôpitaux de Paris, Paris, France.
Emmanuel SorbetsUniversité de Paris, Assistance Publique-Hôpitaux de Paris, Paris, France.ORCID https://orcid.org/0000-0003-0559-6301
Roberto FerrariDepartment of Cardiology, University Hospital of Ferrara and Maria Cecilia Hospital, GVM Care and Research, Cotignola, Italy.
Ian FordRobertson Centre for Biostatistics, University of Glasgow, Glasgow, UK.
Jean-Claude TardifMontreal Heart Institute, Université de Montréal, Montreal, Canada.
Michal TenderaDepartment of Cardiology and Structural Heart Disease, Medical University of Silesia, School of Medicine in Katowice, Katowice, Poland.
Kim M FoxNational Heart and Lung Institute, Royal Brompton Hospital, Imperial College, London, UK.
Philippe Gabriel StegUniversité de Paris, Assistance Publique-Hôpitaux de Paris, Paris, France.ORCID https://orcid.org/0000-0001-6896-2941
Université Paris Cité · FRInserm · FRUniversity of Glasgow · GBMaria Cecilia Hospital · ITMedical University of Silesia · PLMontreal Heart Institute · CARoyal Brompton Hospital · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe COMPASS trial showed a reduction of ischemic events with low-dose rivaroxaban and aspirin in chronic coronary syndromes (CCS) compared with aspirin alone, at the expense of increased bleeding. HYPOTHESIS: The CHA

methodsWe identified the COMPASS-eligible population within the CLARIFY registry (>30.000 patients with CCS). High-bleeding risk patients (REACH BRS > 10) were excluded, as in the COMPASS trial. Patients were categorized as low (0-1) or high (≥ 2) CHA

resultsThe COMPASS-eligible population comprised 5.142 patients with ischemic and bleeding outcome of 2.3 (2.1-2.5) and 0.5 (0.4-0.6) per 100 patient-years, respectively. Patients with intermediate REACH RIS (n = 1934 [37.6%]) had the higher ischemic risk (3.0 [2.6-3.4]) with similar bleeding risk (0.5 [0.4-0.7]) as the overall population. Patients with low CHA

conclusionsIntermediate REACH RIS identified potential optimal candidates for adjunction of low-dose rivaroxaban while patients with low CHA

Indexed as

RegistriesAgedChronic DiseaseComorbidityCoronary Artery DiseaseFemaleFollow-Up StudiesHumansIncidenceMaleRetrospective StudiesRisk AssessmentRisk FactorsSeverity of Illness IndexSwitzerlandSyndromebleeding riskchronic coronary syndromesCOMPASSischemic riskrisk scorerivaroxaban

Identifiers

PMID33274779
PMCPMC7803362
OpenAlexW3108298016

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.